Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies
GK Gupta, AL Collier, D Lee, RA Hoefer, V Zheleva… - Cancers, 2020 - mdpi.com
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
TP53 mutations and outcomes in breast cancer: reading beyond the headlines
A Shahbandi, HD Nguyen, JG Jackson - Trends in cancer, 2020 - cell.com
TP53 is the most frequently mutated gene in breast cancer, but its role in survival is
confounded by different studies concluding that TP53 mutations are associated with …
confounded by different studies concluding that TP53 mutations are associated with …
Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into
distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat …
distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat …
B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer
This study identifies mechanisms mediating responses to immune checkpoint inhibitors
using mouse models of triple-negative breast cancer. By creating new mammary tumor …
using mouse models of triple-negative breast cancer. By creating new mammary tumor …
[HTML][HTML] Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele… - … England Journal of …, 2016 - Mass Medical Soc
Background The genetic and clinical heterogeneity of breast cancer makes the identification
of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively …
of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively …
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …
variable clinical outcomes and responses to conventional chemotherapy. We discovered …
Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following …
IA Mayer, F Zhao, CL Arteaga, WF Symmans… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease
(RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence …
(RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence …
Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized
to be co‐opted by carcinoma during invasion and metastasis. Yet, there is still no …
to be co‐opted by carcinoma during invasion and metastasis. Yet, there is still no …
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Eradicating triple-negative breast cancer (TNBC) resistant to neoadjuvant chemotherapy
(NACT) is a critical unmet clinical need. In this study, patient-derived xenograft (PDX) …
(NACT) is a critical unmet clinical need. In this study, patient-derived xenograft (PDX) …
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
LJ Esserman, IM Thompson, B Reid, P Nelson… - The lancet …, 2014 - thelancet.com
A vast range of disorders—from indolent to fast-growing lesions—are labelled as cancer.
Therefore, we believe that several changes should be made to the approach to cancer …
Therefore, we believe that several changes should be made to the approach to cancer …